1 week Ago By ABMN Staff
Perrigo ( NYSE:PRGO – Get Free Report ) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Friday. A number of other research analysts have also issued reports on the company.
Canaccord Genuity Group reiterated a “buy” rating and set a $42.00 price target on shares of Perrigo in a research report on Monday, September 30th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $30.
00 price objective (down previously from $50.00) on shares of Perrigo in a report on Monday, September 23rd. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock.
According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $37.00. Get Our Latest Stock Analysis on Perrigo Perrigo Stock Performance Perrigo ( NYSE:PRGO – Get Free Report ) last posted its earnings results on Wednesday, November 6th.
The company reported $0.81 EPS for the quarter, hitting the consensus estimate of $0.81.
The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.12 billion.
Perrigo had a negative net margin of 3.64% and a positive return on equity of 7.38%.
Perrigo’s quarterly revenue was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.
64 EPS. As a group, equities analysts anticipate that Perrigo will post 2.56 earnings per share for the current year.
Insider Buying and Selling In other Perrigo news, Director Jeffrey B. Kindler sold 17,598 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $28.
27, for a total transaction of $497,495.46. Following the sale, the director now owns 5,409 shares in the company, valued at approximately $152,912.
43. The trade was a 76.49 % decrease in their position.
The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink . Insiders own 0.70% of the company’s stock.
Hedge Funds Weigh In On Perrigo A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its holdings in shares of Perrigo by 229.2% during the 3rd quarter.
Wellington Management Group LLP now owns 2,697,698 shares of the company’s stock valued at $70,761,000 after acquiring an additional 1,878,145 shares in the last quarter. FMR LLC raised its holdings in shares of Perrigo by 66,795.3% during the 3rd quarter.
FMR LLC now owns 1,840,289 shares of the company’s stock valued at $48,271,000 after purchasing an additional 1,837,538 shares in the last quarter. Diamond Hill Capital Management Inc. boosted its holdings in Perrigo by 83.
2% in the second quarter. Diamond Hill Capital Management Inc. now owns 1,940,067 shares of the company’s stock worth $49,821,000 after purchasing an additional 881,191 shares in the last quarter.
AQR Capital Management LLC increased its position in Perrigo by 675.5% during the second quarter. AQR Capital Management LLC now owns 970,637 shares of the company’s stock worth $24,926,000 after buying an additional 845,470 shares during the last quarter.
Finally, Copeland Capital Management LLC lifted its position in shares of Perrigo by 23.1% in the third quarter. Copeland Capital Management LLC now owns 2,482,544 shares of the company’s stock worth $65,117,000 after buying an additional 465,161 shares during the last quarter.
Institutional investors and hedge funds own 95.91% of the company’s stock. Perrigo Company Profile ( Get Free Report ) Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. Recommended Stories Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.
com's FREE daily email newsletter ..
